Are Strong Financial Prospects The Force That Is Driving The Momentum In Henan Lingrui Pharmaceutical Co., Ltd.'s SHSE:600285) Stock?
Are Strong Financial Prospects The Force That Is Driving The Momentum In Henan Lingrui Pharmaceutical Co., Ltd.'s SHSE:600285) Stock?
Henan Lingrui Pharmaceutical's (SHSE:600285) stock is up by a considerable 5.9% over the past week. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be paying attention to Henan Lingrui Pharmaceutical's ROE today.
河南凌瑞制药(上海证券交易所代码:600285)的股票在过去一周上涨了5.9%。鉴于从长远来看,市场会奖励强劲的财务状况,我们想知道在这种情况下是否如此。特别是,我们今天将关注河南凌瑞制药的投资回报率。
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
股本回报率或投资回报率是用于评估公司管理层利用公司资本效率的关键衡量标准。简而言之,投资回报率显示了每美元从其股东投资中产生的利润。
Check out our latest analysis for Henan Lingrui Pharmaceutical
查看我们对河南灵瑞药业的最新分析
How Do You Calculate Return On Equity?
你如何计算股本回报率?
The formula for return on equity is:
股本回报率的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回报率 = 净利润(来自持续经营)÷ 股东权益
So, based on the above formula, the ROE for Henan Lingrui Pharmaceutical is:
因此,根据上述公式,河南凌瑞药业的投资回报率为:
19% = CN¥526m ÷ CN¥2.7b (Based on the trailing twelve months to September 2023).
19% = 5.26亿元人民币 ¥27亿元人民币(基于截至2023年9月的过去十二个月)。
The 'return' is the profit over the last twelve months. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.19 in profit.
“回报” 是过去十二个月的利润。这意味着,每持有价值1元人民币的股东权益,该公司就会产生0.19元人民币的利润。
What Has ROE Got To Do With Earnings Growth?
投资回报率与收益增长有什么关系?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.
我们已经确定,投资回报率是衡量公司未来收益的有效利润指标。我们现在需要评估公司再投资或 “保留” 了多少利润以用于未来的增长,这样我们就可以了解公司的增长潜力。一般而言,在其他条件相同的情况下,股本回报率和利润保留率高的公司比不具备这些属性的公司的增长率更高。
A Side By Side comparison of Henan Lingrui Pharmaceutical's Earnings Growth And 19% ROE
河南凌瑞制药的收益增长和19%的投资回报率的并排比较
To begin with, Henan Lingrui Pharmaceutical seems to have a respectable ROE. Especially when compared to the industry average of 8.4% the company's ROE looks pretty impressive. This certainly adds some context to Henan Lingrui Pharmaceutical's decent 16% net income growth seen over the past five years.
首先,河南凌瑞药业的投资回报率似乎不错。特别是与行业平均水平的8.4%相比,该公司的投资回报率看起来相当可观。这无疑为河南凌瑞制药在过去五年中实现的16%的净收入增长增添了一些背景信息。
We then compared Henan Lingrui Pharmaceutical's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 11% in the same 5-year period.
然后,我们将河南凌瑞制药的净收入增长与该行业进行了比较,我们很高兴地看到,与同期5年同期增长率为11%的行业相比,该公司的增长数字更高。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231115/0-8da1c02a9c6c041113d16a3cf285fb33-0-ea5be8a574eff2e13f6d134c7f5d46bd.png/big)
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Henan Lingrui Pharmaceutical fairly valued compared to other companies? These 3 valuation measures might help you decide.
为公司附加价值的基础在很大程度上与其收益增长息息相关。投资者接下来需要确定的是,预期的收益增长或缺乏收益是否已经包含在股价中。通过这样做,他们将知道股票是走向清澈的蓝色海水,还是沼泽的水域在等着你。与其他公司相比,河南灵瑞药业的估值是否合理?这3种估值指标可能会帮助您做出决定。
Is Henan Lingrui Pharmaceutical Using Its Retained Earnings Effectively?
河南灵瑞药业有效使用留存收益了吗?
Henan Lingrui Pharmaceutical has a significant three-year median payout ratio of 66%, meaning that it is left with only 34% to reinvest into its business. This implies that the company has been able to achieve decent earnings growth despite returning most of its profits to shareholders.
河南凌瑞制药的三年中位数派息率相当可观,为66%,这意味着它只剩下34%可以再投资其业务。这意味着尽管将大部分利润返还给了股东,但该公司仍能够实现可观的收益增长。
Besides, Henan Lingrui Pharmaceutical has been paying dividends for at least ten years or more. This shows that the company is committed to sharing profits with its shareholders.
此外,河南凌瑞药业已经分红了至少十年或更长时间。这表明该公司致力于与股东分享利润。
Conclusion
结论
In total, we are pretty happy with Henan Lingrui Pharmaceutical's performance. We are particularly impressed by the considerable earnings growth posted by the company, which was likely backed by its high ROE. While the company is paying out most of its earnings as dividends, it has been able to grow its earnings in spite of it, so that's probably a good sign. On studying current analyst estimates, we found that analysts expect the company to continue its recent growth streak. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
总的来说,我们对河南凌瑞制药的表现非常满意。该公司公布的可观收益增长给我们留下了特别深刻的印象,这可能得到了其高投资回报率的支持。尽管该公司将大部分收益作为股息支付,但尽管如此,它还是得以增加收益,因此这可能是一个好兆头。在研究分析师当前的估计时,我们发现分析师预计该公司将继续保持最近的增长势头。要了解有关公司未来收益增长预测的更多信息,请查看这份免费的分析师预测报告,以了解更多信息。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。